[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653273":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":11,"studyPopulation":11,"armGroups":29,"interventions":37,"overallOfficials":47,"centralContacts":52,"locations":61,"responsibleParty":76,"collaborators":11,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":11,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":11,"maxAge":11,"enrollmentInfo":86,"targetDuration":11,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":11,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Nuvectis Pharma, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13,17,20],{"measure":10,"description":11,"timeFrame":12},"Number of patients with treatment related adverse events and\u002For clinical laboratory abnormalities",null,"Up to 30 days post treatment",{"measure":14,"description":15,"timeFrame":16},"Objective response rate (ORR)","Best response of complete response (CR) or partial response (PR) per RECIST 1.1","Up to approximately 12 months",{"measure":18,"description":19,"timeFrame":16},"Duration of Response (DoR)","Confirmed CR or PR from the first documented response to the date of documented disease progression or death.",{"measure":21,"description":22,"timeFrame":16},"Disease Control Rate (DCR)","The proportion of patients with stable disease (SD), partial response (PR), or complete response (CR).",{"allocation":24,"interventionModel":25,"interventionModelDescription":11,"primaryPurpose":26,"observationalModel":11,"timePerspective":11,"maskingInfo":27},"NA","SEQUENTIAL","TREATMENT",{"masking":28,"maskingDescription":11,"whoMasked":11},"NONE",[30],{"label":31,"type":32,"description":33,"interventionNames":34},"Dose Exploration","EXPERIMENTAL","Escalating doses of NXP900 given with lorlatinib",[35,36],"Drug: NXP900","Drug: Lorlatinib",[38,43],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":11},"DRUG","NXP900","NXP900 is an orally administered inhibitor of SRC family kinases (SFK)",[31],{"type":39,"name":44,"description":45,"armGroupLabels":46,"otherNames":11},"Lorlatinib","Lorlatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)",[31],[48],{"name":49,"affiliation":50,"role":51},"Christine Lovly, MD, PhD","City of Hope Medical Center","PRINCIPAL_INVESTIGATOR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":11,"email":57},"Erin Belshaw","CONTACT","2016278129","ebelshaw@nuvectis.com",{"name":59,"role":55,"phone":11,"phoneExt":11,"email":60},"Shay Shemesh","sshemesh@nuvectis.com",[62],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":11},"NEXT Virginia","RECRUITING","Fairfax","Virginia","22031","United States","US",{"type":71,"coordinates":72},"Point",[73,74],-77.30637,38.84622,{"lat":74,"lon":73},{"type":77,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100653273","phase-1-study-of-nxp900-with-lorlatinib-in-alk-lung-cancer-100653273",false,"NCT07784959","Study of NXP900 With Lorlatinib in ALK+ Lung Cancer","A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* 18 years old or older\n* Unresectable, metastatic or locally advanced ALK-positive NSCLC.\n* Must have received lorlatinib as first or second line TKI\n* One prior line of systemic chemotherapy is permitted\n* Must have tolerated the dose level of lorlatinib actively being explored in the study or a higher dose\n\nExclusion Criteria:\n\n* Known single or compound ALK domain mutations that cause resistance to lorlatinib, or known actionable oncogenic driver alterations other than ALK with approved targeted therapies available, such as, MET or EGFR mutations or HER2 overexpression\n* Any contraindications to treatment with lorlatinib according to the lorlatinib United States Prescribing Information (USPI)","ALL",{"count":87,"type":88},54,"ESTIMATED","INTERVENTIONAL",[91],"PHASE1","This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)",[94,95,96,97],"ALK Positive","ALK Positive Non-small Cell Lung Cancer","NSCLC","ALK+ Non-Small-Cell Lung Carcinoma","2026-08-20",{"date":100,"type":101},"2026-08-25","ACTUAL",{"date":103,"type":101},"2026-08-17",{"date":105,"type":88},"2028-02",{"name":5,"class":6},1]